Cardinal Health's Shares Fall as Inflation and Supply Chain Constraints Hit Q3 Earnings

  • Cardinal Health Inc CAH has reported Q3 FY22 adjusted EPS of $1.45, down 5% Y/Y, missing the consensus of $1.52
  • Q2 sales increased 14% Y/Y to $44.8 billion, beating the consensus estimate of $43.16 billion.
  • The pharmaceutical segment increased 17% to $41 billion, driven primarily by branded pharmaceutical sales growth from large Pharmaceutical Distribution and Specialty customers.
  • The medical segment sales decreased 7% to $3.9 billion due to the divestiture of the Cordis business and lower products and distribution volumes, which includes the impact of global supply chain constraints.
  • Related: Washington, Drug Distributors Reach $518M Settlement For Opioid Claims.
  • Outlook: For FY22, Cardinal Health revised adjusted EPS guidance to $5.15 - $5.25 from the previous guidance of $5.15 - $5.50, compared to the consensus of $5.29.
  • The company also updated the Medical segment profit outlook to a 45% - 55% decline, from 30% - 45%. The outlook includes a year-over-year net incremental headwind of nearly $300 million due to inflationary and global supply chain constraint impacts.
  • Price Action: CAH shares are down 3.75% at $58.22 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!